Bone Scan Market Market 2020 Growing Trend And Demand In Healthcare Sector 2023

 Market Synopsis of the Global Bone Scan Market

According to the WHO, about 59% of the mortality is due to chronic diseases and almost 35 million people die of chronic diseases across the globe.

The global bone scan market is expected to grow at a CAGR of 5.7% during the forecast period.

A bone scan is a test of nuclear medicine and is mostly used to diagnose various bone diseases such as arthritis and bone cancer. It includes an injection of radioactive material and then the bone scan. Radioactive material also known as the tracer is injected into a vein. After injecting this material, the radiologist performs a bone scan. The radiologist may perform the bone scan in phases depending upon the condition to be diagnosed such as the presence of bone disease or cancer.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5027

Rising prevalence of bone disease, increasing demand for imaging devices such as MRI, CT scan, SPECT scan, and increasing health care services are accelerating the growth of the market. Furthermore, the increasing expenditure on medical devices influences the market growth. Technological advancements in radiology devices affecting the market growth. However, the efficiency of bone scan may hinder the market growth over the forecast period. Additionally, the bone scan may determine the inaccurate cause of the abnormality.

Key Players in the Global Bone Scan Market   

• Siemens (U.S.)
• Hitachi, Ltd. (Japan)
• Carestream Health, Inc. (U.S.)
• Samsung Electronics Co., Ltd. (South Korea)
• Toshiba Corporation. (Japan)
• Koninklijke Philips N.V. (Netherlands)
• General Electric Company (U.S.)

Segments of the Global Bone Scan Market

The global bone scan market is segmented on the basis of product, indication, device, and end user.

On the basis of the product, the market is segmented into radiopharmaceuticals and imaging devices. The imaging devices are further segmented into Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), and others.

On the basis of the application, the market is segmented into fractures, arthritis, Paget's disease of bone, cancer originating in bone, and others.

On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Regional Analysis

The Americas lead the global bone scan market size owing to the rising prevalence of bone disorders in the U.S. Furthermore, increasing demand for diagnostic services in various also influences the market growth. In North America, the U.S. is the largest market followed by Canada. Increasing penetration of orthopedic specialty hospitals and healthcare insurance is adding fuel to the market growth. Furthermore, the concentration of key players in the market along with the availability of various technologically advanced devices is boosting the market growth in the U.S.

Europe is the second largest bone scan market across the globe. The market is accelerated by the extensive use of diagnostic devices for diagnosis of various chronic diseases such as arthritis, diabetes, obesity and others. Furthermore, extensive research and development (R&D) activities carried out by clinical research and academic institutes stimulate the growth of the market. Germany and France contribute to the growth of the market owing to increasing expenditure on R&D and extensive demand for diagnostic devcies.

The Asia Pacific market is expected to grow at the fastest pace due to the high prevalence of chronic disease such as rheumatoid arthritis, osteoarthritis, obesity, diabetes, and other. Additionally, increasing number of bone injuries such as bone fractures boost the growth of the market.  To add further, increasing number of skilled professionals along with increasing awareness about the bone diseases and importance of imaging tests in the diagnosis of bone diseases, and injuries. In Asia Pacific, India and China are holding the largest market share followed by Japan. Increasing expenditure on healthcare and improving healthcare infrastructure in various developing regions of Asia Pacific region are affecting the market growth, positively.

 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bone-scan-market-5027

Global Brain Dead Diagnosis & Treatment Market 2020 – Investment Strategy, Outlook And Key Development Till 2023

 Market Scenario

The increasing incidence of accidents and brain injury is leading to shift from treatment to oragn donation procedures are some factors responsible for the growth of the global brain dead diagnosis and treatment market.

A brain-dead patient is supposed to have no clinical evidence of brain function upon physical examination. The examination exhibits no cranial nerve reflexes and no response to pain. The reflexes include no spontaneous respirations, oculocephalic reflex, pupillary response (fixed pupils), corneal reflex, and no response to the caloric reflex test. According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

It is of utmost important to distinguish brain death and other states that may be difficult to differentiate from brain death, such as alcohol intoxication, chronic vegetative states, barbiturate overdose, hypoglycemia, hypothermia, coma, and sedative overdose. Few comatose patients can recover to pre-coma level of functioning, and some patients with severe irreversible neurological dysfunction will nonetheless retain some lower brain functions, such as spontaneous respiration, despite the losses of both cortex and brain stem functionality in case of anencephaly. However, limited availability of facilities and higher treatment cost may hamper the brain dead diagnosis and treatment market growth during the forecast period.

The global market of brain dead diagnosis and treatment is expected to grow at a CAGR of approximately 7% during the forecast period 2017-2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4997

Intended Audience

• Brain Dead Diagnosis and Treatment Suppliers
• Brain Dead Diagnosis and Treatment Trends
• Brain Dead Diagnosis and Treatment Manufacturers
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Segmentation

The brain dead diagnosis and treatment market is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of diagnosis, it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG), radionuclide angiography, cerebral arteriography, nuclear brain scanning, transcranial doppler ultrasonography

On the basis of treatment, it is segmented into medical treatment, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.

Key Players in the Global Brain Dead Diagnosis and Treatment Market    

Some of key the players in the Global Brain dead diagnosis and Treatment Market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others

Regional Analysis

The global brain dead diagnosis and treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America dominated the global brain dead diagnosis and treatment market owing to the increasing healthcare expenditure. In the United States, if the patient is at or near death, the hospital must notify a transplant organization of the person's details and maintain the patient while the patient is being evaluated for suitability as a donor. The patient is kept on ventilator support until the organs have been surgically removed. Furthermore, increased R&D activities and the concentration of major companies have fueled the growth of the market in this region.

Europe holds the second position in the global brain dead diagnosis & treatment market owing to the government support for research & development and availability of funds for research. For instace, in countries such as Spain, Finland, Poland, Wales, Portugal, and France, everyone is automatically an organ donor after diagnosis of death on legally accepted criteria, although some jurisdictions such as Singapore, Spain, Wales, France, Czech Republic and Portugal allow opting out of the system. Elsewhere, consent from family members or next-of-kin may be mandatory for organ donation.

Asia Pacific is the fastest growing brain dead diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries such as New Zealand, Australia, drivers are asked upon application if they wish to be registered as an organ donor are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region. 

Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/brain-dead-diagnosis-and-treatment-market-4997 

Ebstein’s Anomaly Market 2020 Covers Global Industry Share, Size, Gross Margin, Future Trends, Demand, Business Insight By Leading Key Players Forecast Till 2023

 Market Scenario:

Ebstein's anomaly is a rare congenital disease that occurs due to improper development of the tricuspid valve in the first eight weeks of fetal growth. This disorder occurs when the tricuspid valve that divides the two chambers of the right side of the heart does not form correctly.

The global Ebstein’s Anomaly market is driven by the increasing number of congenital heart diseases and growing population; growing market players has increased the scope of Ebstein’s Anomaly market. Technological advancements, owing to which new and advanced products are being launched in the market, is another factor propelling the growth of this market.

Ebstein's anomaly may be due to many factors, including genetics and the environment. Children born in a family with a history of heart defects may be more likely to have Ebstein's anomaly. The mother's exposure to certain medications, such as lithium, can lead to Ebstein's anomaly in the child.

However, varied stringency of regulatory procedures across the globe and the presence of complex regulatory procedures may hinder the growth of this market.

The global Ebstein’s Anomaly market share is expected to grow at a CAGR of 9.0% during the forecast period.

Key Players                                                                                                         

Some of the key players in fungal eye infection market are Ebstein’s Anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, Ge Healthcare, Gore Medical, Medtronic, Inc., Numed, Inc., Siemens Healthcare, St. Jude Medical, and Toshiba Corporation among others.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5633

Segmentation                                                                                                                                            

The global Ebstein’s Anomaly market is segmented on the basis of treatment, diagnosis and end users.

On the basis of diagnosis Ebstein’s Anomaly market is segmented into echocardiogram, electrocardiogram (ECG) chest x-ray, cardiac MRI, Holter monitor, pulse oximetry, exercise stress test, electrophysiology study, and cardiac catheterization.

On the basis of the treatment, the market is segmented medications and surgical treatment. Surgical Treatment is further segmented into tricuspid valve repair, tricuspid valve replacement, closure of the atrial septal defect, and maze procedure.

On the basis of end users, the market is segmented into hospitals & surgical centers, and specialty clinics.

Regional Analysis

North America Ebstein’s Anomaly market is rapidly growing in the American region. On a regional basis, the Americas is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of congenital disorders and growing  population has increased the scope for the Ebstein’s Anomaly market in North America. According to CDC (Centre for Disease Control), it was estimated that about 1 million U.S. children and about 1.4 million U.S. adults were living with CHDs.  Additionally, CHDs affect nearly 1% of―or about 40,000―births per year in the United States.

Europe is the second largest market and holds a healthy share in the global Ebstein’s Anomaly market. The European market is expected to grow steadily during the forecast period owing to the skilled professionals and availability of advanced and accessible treatment facilities. Additionally, wide research and development activities for the treatment of rare disease and increasing government funding boost the market growth.  

Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes is the major driver for the market growth. India is the fastest growing region owing to the increasing population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drives the market.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ebstein-s-anomaly-market-5633

Dry Eye Syndrome Market 2020: Size, Upcoming Trends, On-Going Demand, Growth And Forecast From 2020 To 2023 With Most Prominent Key Players

 Increasing geriatric population, rising prevalence of the diseases like diabetes, rheumatoid arthritis, growing per capita healthcare expenditure, and changing lifestyle are the major drivers for the market growth. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are estimated to restrain the market growth during the forecast period. 

The global dry eye syndrome market growth is expected to advance with an approximate CAGR of 6.6% during the forecast period.

According to the World Health Organization in 2016, approximately 422 million adults were globally affected by diabetes in 2014, as compared to 108 million in the 1980’s. Moreover, in 2014, it was estimated that the global prevalence of diabetes was estimated to be around 8.5%. Additionally, rising per capita healthcare expenditure, and changing lifestyle boosts the market. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle-and low-income countries are restraining the market. 

Tears provide lubrication, limits the risks of eye infections, washes away the foreign matter, thus, are helpful in keeping the surface of the eyes smooth and clear. Dry eye syndrome is a medical condition in which eyes’ lubrication is hindered by the unavailability of tears. Under normal condition, during excessive production, tears flow into the small drainage ducts of the inner corners of the eyes, followed by draining back into the nose. Sometimes when the production of tears and drainage is not balanced, it can result into dry eye syndrome. Eye redness, sensitivity to light, watery eyes, eye fatigue are some of the common symptoms of the disease. Increasing geriatric population, rising prevalence of diseases like diabetes, rheumatoid arthritis, and others are estimated to be the major drivers for the market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5588  

Key Players

The key players for the global dry eye syndrome are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.

Segmentation

The global dry eye disease market is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.

On the basis of the type, the market is segmented into evaporative dry eye syndrome aqueous dry eye syndrome, and others. On the basis of the diagnosis, the market is categorized into Schirmer test, eye exam, and others.  On the basis of the treatment, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segement is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.  On the basis of the end users, the market is segmented into hospitals, clinics, home care, and others.

Regional Analysis

The Americas dominates the global dry eye syndrome market owing to the presence of a well-developed healthcare sector, huge patient population, and increasing healthcare expenditure. Moreover, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region boosts the market growth. Europe stands second in the dry eye syndrome market. This is attributed to the increasing availability of funds for research, a well-developed healthcare sector, huge patient and growing geriatric population. The Asia Pacific region is estimated to be the fastest growing region for the market. Economies like India, China, Australia and others within the region have huge patient population, rising healthcare expenditure facilitating the market growth. On the other hand, the Middle East & Africa has the least share in the global dry eye syndrome. Low per capita healthcare expenditure, stringent government policies, especially within the African region restrains the market growth within the region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.

Browse Premium Research Report Enabled with Respective Tables and Figures @  https://www.marketresearchfuture.com/reports/dry-eye-syndrome-market-5588 

Uterine Sarcoma Market 2020 Global Trend, Segmentation And Opportunities, Forecast 2023

 Market Scenario:

Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016.

Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.

The global uterine sarcoma treatment market is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5131 

Key players

• Pfizer Inc.
• Intas Pharmaceuticals Ltd.
• FMC Corporation
• Sun Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• General Electric Company
• Koninklijke Philips N.V.
• Siemens Healthcare Private Limited

 

Segmentation

The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.

On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.

On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.

On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.

Regional Analysis

Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.

America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.

Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population.  By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.

The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/sample_request/5131

Fungal Endocarditis Market 2020 Global Growth Insights, Trends, Size, Share And Forecast To 2023

 Fungal Endocarditis Market Information: By Type of Fungus (Candida, Aspergillus), Diagnosis (Blood Test, X-Ray, Echocardiography, Electrocardiogram), Treatment (Antifungal Medication, Surgery, Combined Treatment), End User - Global Forecast till 2023

Fungal endocarditis is an infection of the heart’s inner lining, known as the endocardium. The etiologic fungi more commonly observed are the Candida and Aspergillus species.

The gold standard for the diagnosis of fungal endocarditis is culture and the isolation of etiologic agents from infected valves, emboli, and other materials collected by different invasive methods such as surgery.

A number of factor such as rising incidents of fungal endocarditis, increasing awareness about fungal infections, improving regulatory framework, increasing government assistance, and rising funding and reimbursement are propelling the growth of the global fungal endocarditis market.

It is estimated that the fungal endocarditis treatment market is expected to grow at a CAGR 4.2% during the forecast period of 2017-2023.

However, challenges in research and development, side-effects of treatment, presence of misbranded and spurious drugs and poor healthcare system in low and middle-income countries may hamper the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5115

Key Players

Some of key the players in the global fungal endocarditis market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, and Others. 

Segmentation

The global fungal endocarditis market is segmented on the basis of type of causative agent, diagnosis, treatment, and end-user.

On the basis of the treatment, the market is classified as antifungal medication, surgery, and combined treatment. The antifungal medication is further segmented into voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, and others.

On the basis of the type of causative agent, the market is segmented into Candida species

Aspergillus species, and Histoplasma capsulatum.

On the basis of the diagnosis, the market is classified into physical examination, blood test, X-ray, echocardiography, and electrocardiogram

On the basis of the end-users, the market is segmented into hospital, clinics, diagnostic centers, and others.

Regional Analysis

The Asia Pacific is the fastest growing fungal endocarditis market share owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Americas dominate the fungal endocarditis market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the fungal endocarditis market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.

The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/fungal-endocarditis-market-5115 

Acoustic Neuroma Market By Key Vendors, Regions, Trends With Industry Study & Forecast To 2023

 The global acoustic neuroma treatment market is expected to grow at a CAGR of approximately 7.6% during the forecast period 2017-2023.

Market Scenario

Acoustic neuromas also known as vestibular schwannomas, usually grows slowly over a period of years. Usually they do not invade the brain, but can push on it as they grow. As the tumor grows, they press the nearby cranial nerves that control the muscles enabling facial expression and sensation. If the tumor becomes large enough to press on the brain stem or cerebellum, it can be deadly. They account for almost 8% of all tumors inside the skull. The prevalence rate is 1 out of every 100,000 individuals per year.

An acoustic neuroma is a non-cancerous (benign) growth that develops on the 8th cranial nerve (vestibulocochlear nerve), it connects the inner ear with the brain and has two different parts. One part is involved in transmitting sound and the other sends balance information to the brain.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5107

Acoustic neuromas are mainly categorized into unilateral and bilateral vestibular schwannomas. Unilateral affect only one ear and bilateral vestibular schwannomas affect both hearing nerves and are usually associated with some genetic disorder. More than half of the affected individuals have inherited the disorder from an affected parent. Several new drugs are launched by the key players which grants various opportunities for the global acoustic neuroma market.

Usually these neuromas are rare. Globally around 1-20 people in every million are diagnosed each year with an acoustic neuroma. Acoustic neuromas account for about 6 cases in every 100 patients with brain tumours. They are more common in middle-aged adults and are rare in children. Furthermore,  these neuromas seem to be more common in women than in men. Acoustic neuromas tend to affect adults aged 30 to 60 and usually have no obvious cause, although a small number of cases are the result of a genetic condition called neurofibromatosis type 2 (NF2).

The gadolinium enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis of vestibular schwannoma yet several examinations may arise suspicion of vestibular schwannomas. According to a patient survey held by the Acoustic Neuroma Association, in 2012, it was reported that after surgical treatment of acoustic neuroma more than 35% patients suffered a headache depending on the type of surgical approach, technique used and the time since surgery.

Top Key Acquisitions

Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.

Some of key the players in the global acoustic neuroma market are GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis AG, Pfizer Inc., and others

Segmentation

The acoustic neuroma is segmented on the basis of type, diagnosis, drug class, treatment, and end-users.

On the basis of type, the market is segmented into unilateral vestibular schwannomas and bilateral vestibular schwannomas.

On the basis of diagnosis, the market is segmented into hearing test (audiometry), electronystagmography, magnetic resonance imaging (MRI), and others.

On the basis of end-user, the market is segmented into hospitals, diagnostic centers, academic and research institutes, and others.

On the basis of drug class, the market is segmented into anticonvulsants, corticosteroids, osmotic diuretics and pain killers.

On the basis of treatment, the market is segmented into monitoring, surgery, radiation therapy, supportive therapy and others. The radiation therapy is sub segmented stereotactic radiotherapy, proton beam therapy. Surgery is sub segmented radiosurgery, craniotomy, and microsurgery removal

Regional Analysis

The global acoustic neuroma market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America is projected to hold the largest share of the global acoustic neuroma market due to presence of huge numbers of key players supporting research and development for developing novel therapies, large base of diagnostic centers and greater emphasis on disease prevention and wellness by governments. Along with that healthcare facilities in the U.S. are gradually moving from treatment to wellness, so the prevention and early detection of disease is critical. Approximately 2,000 to 3,000 cases are diagnosed each year with acoustic neuroma in the United States (6 to 9 per million persons).

The European acoustic neuroma market hold the second largest market as it witness rapid growth. According to NHS U.K, an acoustic neuroma can occasionally return after treatment. This is thought to happen to around 1 in every 20 people who have had surgical removal.

Asia Pacific is expected to be the most promising markets for acoustic neuroma in the near future The Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/acoustic-neuroma-market-5107